证券代码：688575 证券简称：亚辉龙 公告编号：2025-075 深圳市亚辉龙生物科技股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 12 月 26 日 （二） 股东大会召开的地点：广东省深圳市龙岗区宝龙街道高科大道 32 号启德 大厦 8 栋会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 89 | | --- | --- | | 普通股股东人数 | 89 | | 2、出席会议的股东所持有的表决权数量 | 217,252,948 | | 普通股股东所持有表决权数量 | 217,252,948 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 38.0219 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | ...

东省深圳市福田区中心 四路 1-1 号 嘉里建设广场第三座第 28 层 2803-04 室 曲话. (86-755) 2939-5288 传直:(86-755)2939-5289 iunhesz@iunhe.com 北京市君合(深圳)律师事务所 关于深圳市亚辉龙生物科技股份有限公司 2025 年第二次临时股东大会的法律意见书 致:深圳市亚辉龙生物科技股份有限公司 北京市君合(深圳)律师事务所(以下简称"本所")接受深圳市亚辉龙生物 科技股份有限公司(以下简称"贵公司"或"公司")的委托,就贵公司 2025年第二 次临时股东大会(以下简称"本次股东大会")召开的有关事宜,根据《中华人民 共和国公司法》(以下简称"《公司法》")、《中华人民共和国证券法》、中国证券 监督管理委员会颁布的《上市公司股东会规则》(以下简称"《股东会规则》")等 中国现行法律、法规、规章、规范性文件(以下简称"中国法律、法规",仅为 本法律意见书法律适用之目的,不包括中国香港特别行政区、中国澳门特别行政 区及中国台湾省的法律法规)及现行《深圳市亚辉龙生物科技股份有限公司章程》 (以下简称"《公司章程》"）的有关规定,出具本法律意见书。 ...

关于选举职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《中华人民共和国公司法》（以下简称"《公司法》"）《上市公司章程指引 （2025 年修订）》《上海证券交易所科创板股票上市规则（2025 年 4 月修订）》（以 下简称"《科创板上市规则》"）等法律法规及规范性文件的相关规定，深圳市亚辉龙 生物科技股份有限公司（以下简称"公司"）将于 2025 年 12 月 26 日召开 2025 年第二 次临时股东大会，审议《关于修订<公司章程>暨取消监事会、设置职工代表董事的议 案》，公司拟在董事会中设置职工代表董事一名，根据其在公司的实际岗位职务，按照 公司薪酬绩效考核方案领取薪酬，不额外领取董事津贴。职工代表董事由公司职工通过 职工代表大会民主选举产生，无需提交股东会审议。 证券代码：688575 证券简称：亚辉龙 公告编号：2025-074 鉴于上述情况，公司于 2025 年 12 月 25 日召开职工代表大会，审议通过了《关于 选举第四届董事会职工代表董事的议案》，同意选举杨韦先生为公司第四届董事会 ...

格隆汇12月25日丨亚辉龙(688575.SH)公布，公司于2025年12月25日召开职工代表大会，审议通过了 《关于选举第四届董事会职工代表董事的议案》，同意选举杨韦先生为公司第四届董事会职工代表董 事。 ...

格隆汇12月25日丨亚辉龙(688575.SH)公布，公司于2025年12月25日召开职工代表大会，审议通过了 《关于选举第四届董事会职工代表董事的议案》，同意选举杨韦先生为公司第四届董事会职工代表董 事。 ...

Investment Rating - The industry rating is "Overweight" and has been maintained from the previous rating [4] Core Insights - The global IVD market is projected to grow from USD 66.7 billion in 2018 to USD 186.1 billion by 2030, with a CAGR of 8.9% [12] - The Chinese IVD market is expected to increase from RMB 71.3 billion in 2018 to RMB 415.2 billion by 2030, with a CAGR of 15.8%, significantly outpacing the global average [13] - The immunodiagnostics market in China is experiencing rapid growth, with a market size increase from RMB 37.3 billion in 2021 to RMB 50.3 billion in 2023, reflecting a CAGR of 16.13% [16] - The POCT market is also expanding quickly, growing from RMB 11.2 billion in 2021 to RMB 16 billion in 2023, with a CAGR of 19.52% [20] - The molecular diagnostics market, despite a decline from RMB 23.1 billion in 2021 to RMB 14.8 billion in 2023, still shows potential with a market size exceeding RMB 10 billion when excluding emergency-related factors [25] Summary by Sections IVD Market Outlook - The IVD industry began in the 1950s and has seen significant growth due to advancements in medical technology and increasing health demands [11] - The Chinese IVD market has diversified into various diagnostic technologies, including biochemical, immunological, POCT, molecular, and pathological diagnostics [15] Immunodiagnostics Market - The immunodiagnostics market is the largest segment in China's IVD market, accounting for over 40% in 2023 [15] - The market is expected to face some deceleration due to price reductions from centralized procurement policies [16] Biochemical Diagnostics Market - The biochemical diagnostics market in China grew from RMB 17.1 billion in 2021 to RMB 19 billion in 2023, with a CAGR of 5.41% [19] - Domestic products dominate this market with over 70% market share [19] POCT Market - The POCT market is driven by convenience and increased demand for home testing, growing from RMB 11.2 billion in 2021 to RMB 16 billion in 2023 [20] Molecular Diagnostics Market - The molecular diagnostics market has faced challenges, declining from RMB 23.1 billion in 2021 to RMB 14.8 billion in 2023, primarily due to reduced demand post-pandemic [25] Pathogen Microbiology Market - The pathogen microbiology diagnostics market in China is projected to grow from RMB 16.82 billion in 2018 to RMB 90.27 billion by 2030, with a CAGR of 15.0% [30]

Group 1 - Shareholder of Okoyi plans to reduce holdings by up to 1.89% of the company's shares, amounting to a maximum of 3 million shares due to personal funding needs [1] - Tianchuang Fashion is planning a change in control, leading to continued suspension of its stock trading, expected to last no more than 3 trading days [2] - China Electric Power Construction Company reported a new contract amount of 10,317.55 billion yuan for the first 11 months of 2025, a year-on-year decrease of 1.65% [3] Group 2 - Pilin Bio's wholly-owned subsidiary received approval for a clinical trial of a drug, indicating progress in its product development [4] - Yihong Medical obtained two medical device registration certificates for diagnostic kits, enhancing its product portfolio [5] - Aohong Electronics plans to use up to 450 million yuan of idle fundraising for cash management, targeting safe and liquid financial products [6] Group 3 - China Electric Power Construction signed a contract worth approximately 6.626 billion yuan for a natural gas booster station project in Turkey, with a construction period of about 55 months [7] - Baosheng Co. won a bid for a power cable project in Singapore, valued at around 1.2 billion yuan, marking the largest overseas order in its history [8] - *ST Xinyan's stock will resume trading on December 24, 2025, following a capital increase plan that will raise its total share capital to 3.29 billion shares [9] Group 4 - Ningbo Construction's subsidiary signed a construction contract worth 428 million yuan for an engineering project with a duration of 990 days [11] - Lianhuan Pharmaceutical's subsidiary received approval for a drug that passed the consistency evaluation for generic drugs, enhancing its market competitiveness [12] - Zhongjie Automotive received a project designation for a new electric air conditioning compressor, with expected sales of approximately 29.86 million USD over its lifecycle [13] Group 5 - Biopharmaceuticals' major shareholder plans to increase holdings by 50 million to 100 million yuan, indicating confidence in the company's future [14] - Haizheng Pharmaceutical's subsidiary received approval for a veterinary drug product, expanding its product offerings in the animal health sector [15] - *ST Songfa's subsidiary signed contracts for the construction of 8 vessels, with a total contract value between 200 million to 400 million USD [16] Group 6 - Shandong Pharmaceutical Glass announced the resignation of its chairman due to age reasons, indicating a potential leadership transition [17] - Xinno Wei's subsidiary received approval for a clinical trial of a monoclonal antibody drug, indicating advancements in its drug development pipeline [18] - Ningbo Huaxiang's subsidiary secured an order for robot joints, expected to positively impact future business performance [19][20] Group 7 - China Resources Double Crane's subsidiary received approval for a clinical trial of a drug aimed at treating a genetic eye disease, reflecting ongoing R&D efforts [21] - Huaxin Technology's shareholders set a transfer price of 56.69 yuan per share for a block of shares, indicating active shareholder engagement [22] - Xinhua Net announced the resignation of its president due to job relocation, suggesting potential changes in management [23] Group 8 - Taiji Group plans to transfer a 40% stake in a subsidiary to focus on its core pharmaceutical business, enhancing operational efficiency [24] - Huaxin Construction's shareholder plans to increase holdings by 200 million to 400 million yuan, reflecting confidence in the company's prospects [25] - Dongjie Intelligent is planning to issue shares and cash for asset acquisition, with stock trading suspended until further notice [26] Group 9 - Wanrun New Energy was designated as a delivery warehouse for lithium carbonate futures, indicating its strategic position in the market [27] - Prolo Pharmaceutical's subsidiary received a drug registration certificate for an influenza treatment, expanding its product range [28] - Saiwu Technology invested 5 million yuan in a private equity fund focused on smart vehicles and energy innovation, indicating strategic investment in growth sectors [29] Group 10 - Bohui Innovation's subsidiary received approval for a clinical trial of an immunoglobulin drug, indicating progress in its product development [30] - Bohui Innovation's subsidiary also received a drug registration certificate for a coagulation factor product, enhancing its therapeutic offerings [31] - Hanghua Co. plans to allocate 146 million yuan of surplus fundraising for a new green printing materials project, reflecting a commitment to sustainability [32] Group 11 - Nova Star Cloud obtained a loan commitment letter from a bank for a share repurchase plan, indicating financial support for its capital management strategy [33] - Jimin Health established a joint venture for technology innovation, indicating a strategic move to enhance its technological capabilities [34] - Huili Pharmaceutical received a drug registration certificate for a medication used in treating digestive ulcers, expanding its product portfolio [35]

智通财经APP讯，亚辉龙(688575.SH)发布公告，公司及全资子公司湖南亚辉龙生物科技有限公司于近 日分别收到了由广东省药品监督管理局和湖南省药品监督管理局签发的医疗器械注册证，产品名称：涎 液化糖链抗原(KL-6)测定试剂盒(化学发光法)、抗黑色素瘤分化相关基因5IgG抗体测定试剂盒(化学发光 法)。 ...

亚辉龙(688575.SH)发布公告，公司及全资子公司湖南亚辉龙生物科技有限公司于近日分别收到了由广 东省药品监督管理局和湖南省药品监督管理局签发的医疗器械注册证，产品名称：涎液化糖链抗原(KL- 6)测定试剂盒(化学发光法)、抗黑色素瘤分化相关基因5IgG抗体测定试剂盒(化学发光法)。 ...

Group 1 - The company, Aihua Long (688575), announced on December 23 that it has received medical device registration certificates from the Guangdong and Hunan Provincial Drug Administration [1] - The registered products include the saliva liquefaction sugar chain antigen (KL-6) detection kit (chemiluminescence method) and the anti-melanoma differentiation-associated gene 5 IgG antibody detection kit (chemiluminescence method) [1]